← Eichor
Study identifier: NCT06578520 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure

Condition: Heart Failure  ·  Sponsor: Fundación para la Investigación del Hospital Clínico de Valencia

PhasePhase 4
Planned participants31
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Cross-over, 2-sequence, 2-treatment, 2-period single-centre, phase IV, randomized, open label study.

This description comes directly from the study's public registry record.

Talk to the study team

Marco Montomoli  ·  961 973500  ·  marcomontomoli@hotmail.it

Always discuss trial participation with your own doctor first.

Locations (1)

Hospital Clínico Universitario de ValenciaValencia, SpainRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06578520